Anti-LAG-3 antibodies and methods of use thereof

US12187795B2 · kind B2 · utility

Assignee

• Agenus Inc. · US

Inventors

• Nicholas Stuart Wilson · Melbourne, AU
• David Adam Savitsky · Boxford, US
• Shawn Michael Jennings · Acton, US
• Marc van Dijk · Bosch en Duin, NL
• Cornelia Anne Mundt · Lörrach, DE

Key dates

• Filing date: Oct 23, 2020
• Grant date: Jan 7, 2025
• Expiry date: Jul 25, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.